Relay Therapeutics reported a narrower-than-expected net loss of $81.7 million for the third quarter of 2026, compared to the consensus estimate of $83.75 million. Although the company recorded zero revenue for the quarter, it achieved a major clinical milestone with the first FDA approval of a molecule discovered via its Dynamo platform and significantly extended its projected cash runway.
Key Highlights
- Net loss per share of $0.37 improved from a $0.43 loss in the prior year and outperformed the estimated $0.40 loss.
- Research and development expenses rose to $77.1 million from $68.3 million YoY, primarily due to accelerated clinical trial activity and non-recurring lease termination costs.
- Management extended its cash runway guidance into 2029, up from late 2027, underpinned by a quarter-end cash and investments balance of $848.6 million.
- The FDA granted full approval for lirafugratinib (LYRFIGTU) in cholangiocarcinoma, a molecule discovered by Relay and licensed to Elevar Therapeutics.
- The pivotal Phase 3 ReDiscover-2 trial for zovegalisib is now expected to complete enrollment in mid-2027, approximately one year ahead of recent industry benchmarks.